Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

2 1

What is this study about?

The study focuses on adults with heart failure with reduced ejection fraction, a condition where the heart does not pump blood as well as it should. Participants will receive either the experimental oral tablet CRD-4730 or a matching placebo tablet. The aim of the trial is to evaluate the effect of the medication on overall heart health and safety.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

1 randomization and receipt of study medication

after you have joined the study, you will be assigned randomly to receive either the active drug or a matching placebo. the assignment is done by the study team and you will not know which one you receive.

you will be given a bottle containing tablets. each tablet contains 150 mg of crd-4730 if you are in the active group, or a matching placebo tablet if you are in the control group. the tablets are taken by mouth.

2 daily medication intake

you will take one tablet each day, preferably at the same time each day, for a total of 24 weeks. the tablet is swallowed whole with water and should be taken with or without food.

if you experience any side effects, you should record them in the diary provided and inform the study staff at the next visit.

3 first follow‑up visit (week 12)

after 12 weeks of taking the tablet, you will return to the clinic for a follow‑up visit. during this visit, blood will be drawn to measure a marker called nt-probnP, and an echocardiogram (ultrasound of the heart) will be performed to check heart size and function.

you will also complete a questionnaire about your heart‑failure symptoms and quality of life. the study staff will check your vital signs, review any side effects, and ensure the medication is being taken as directed.

4 final visit (week 24)

at the end of 24 weeks, you will attend the final study visit. the same set of tests performed at week 12 will be repeated, including blood tests, echocardiogram, and the symptom questionnaire.

the study team will collect information about any adverse events that occurred during the study and will assess the overall safety and effectiveness of the treatment.

after the final assessments, you will stop taking the study tablet. the study staff will discuss any further care you may need.

Who Can Join the Study?

Be at least 18 years old and not older than 85 years at the time of screening.
Have a medical history of chronic heart failure for at least 8 weeks and currently be in NYHA functional class II or III (meaning you have mild to moderate symptoms with everyday activities).
Show a left ventricular ejection fraction (EF) of 40% or less on a transthoracic echocardiogram (an ultrasound test that pictures the heart’s pumping ability).
Have a blood level of N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP) of at least 600 pg/mL at screening. If you have atrial fibrillation or flutter (an irregular heart rhythm), the required level is at least 900 pg/mL.
Be taking a stable and optimized set of medicines that follow the recommended guideline‑directed heart‑failure therapy (the standard drugs for heart failure that have been adjusted and kept steady).
Meet any additional study‑specific requirements that are defined in the trial protocol.

Who Cannot Join the Study?

You cannot join if you have had a recent worsening of heart failure that required a hospital stay or medicines given through a vein (intravenous (IV)) or under the skin (subcutaneous (SQ)) to remove extra fluid (diuretics) within the past 4 weeks.
You cannot join if you need regular outpatient IV infusions for heart failure, such as strong heart‑boosting drugs (inotropes), medicines that widen blood vessels (vasodilators), or diuretics, or if you routinely have a fluid‑removal procedure called ultrafiltration.
You cannot join if you have had a recent heart attack or related problems, including sudden chest pain that is unstable (unstable angina), ongoing chest pain while at rest, a stroke, a brief stroke‑like episode (transient ischemic attack), major heart or neck‑vessel surgery, repair or replacement of heart valves, or a neck‑vessel opening procedure (carotid angioplasty) within the past 8 weeks.
You cannot join if doctors suspect you have other heart muscle diseases, such as build‑up of abnormal proteins (amyloid) or inflammatory cell clusters (sarcoid), a thickened heart muscle condition (hypertrophic cardiomyopathy), heart failure caused by very severe valve problems, active inflammation of the heart muscle (myocarditis), inflammation of the lining around the heart (pericarditis), or a significant birth‑related heart defect (congenital heart disease).
You cannot join if any other study‑specific reasons listed in the trial protocol apply.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
IRCCS Humanitas Research Hospital	Rozzano	Italy
Azienda Ospedaliero Universitaria Careggi	Florence	Italy
Premedix	Bratislava	Slovakia

Other Sites

Site Name	City	Country
Pauls Stradins Clinical University Hospital	Riga	Latvia
Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta	Caserta	Italy
Centro Cardiologico Monzino S.p.A.	Milan	Italy
Universita Degli Studi Di Brescia	Brescia	Italy
University Hospital Bratislava	Bratislava	Slovakia
Adoria SIA	Riga	Latvia
Kardiocentrum Nitra s.r.o.	Nitra	Slovakia
Alian s.r.o.	Bardejov	Slovakia
Medispol s.r.o.	Presov	Slovakia
Daugavpils regionala slimnica SIA	Daugavpils	Latvia
Cardio D&R s.r.o. Kosice	Kosice	Slovakia
Medivasa s.r.o.	Zilina	Slovakia
Haga Hospital	Hague	The Netherlands
Saules seimos medicinos centras UAB	Kaunas	Lithuania
Pratia Pardubice a.s.	Pardubice	Czechia
Vilniaus universiteto ligonine Santaros klinikos VšĮ	Vilnius	Lithuania
Fakultni Nemocnice Hradec Kralove	Novy Hradec Kralove	Czechia
Fakultni Nemocnice U Sv Anny V Brne	Brno-Stred	Czechia
Deventer Ziekenhuis	Deventer	The Netherlands
Vseobecna Fakultni Nemocnice V Praze	Prague	Czechia
Gelre Hospitals	Zutphen	The Netherlands
Klaipedos universiteto ligonine VšĮ	Klaipeda	Lithuania
Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos	Kaunas	Lithuania
KardioBusak s.r.o.	Louny	Czechia
Medisch Spectrum Twente	Enschede	The Netherlands
Diakonessenhuis Stichting	Utrecht	The Netherlands
Saxenburgh Medisch Centrum	Hardenberg	The Netherlands
Respublikine Panevezio ligonine VšĮ	Panevezys	Lithuania
Edumed s.r.o.	Jaromer	Czechia
Rorwd Arxcjfjf kxfwpilb uwuocrcvsueew smrnltow Sxq	Riga	Latvia
Avxbiak Otmzulcvcnz Pcvh Gcynbohm Xvanv	Bergamo	Italy
Kimbubpchpmccuyxxa scyagq	Prague	Czechia
Uwfsycgrxela Mageiel Clenlol Geitzqrln	Groningen	The Netherlands

Trial status

Country	Status	Recruitment Start
Czechia	Not yet recruiting	11.09.2026
Italy	Not yet recruiting	11.09.2026
Latvia	Not yet recruiting	11.09.2026
Lithuania	Not yet recruiting	11.09.2026
Slovakia	Not yet recruiting	11.09.2026
The Netherlands	Not yet recruiting	11.09.2026

Trial locations

Investigated Drugs:

Crd-4730

CRD-4730 is an experimental oral tablet being tested to see if it can improve heart function in people with heart failure that has a reduced ejection fraction. In this study, participants take the tablet by mouth, and researchers compare their health outcomes to those of participants who receive a placebo. The goal is to find out whether the medicine can lower the risk of heart-related problems, such as hospitalization or worsening symptoms, and whether it is safe and well‑tolerated for patients.

Heart failure with reduced ejection fraction – A condition in which the heart’s main pumping chamber becomes weakened and cannot contract strongly enough to move blood efficiently. This reduced pumping ability leads to a buildup of fluid in the lungs and other parts of the body. Over time, the heart may enlarge and the symptoms, such as shortness of breath and swelling, can become more noticeable as the disease slowly progresses.

Trial ID:

2025-525033-31-00

Protocol code:

CRD-4730-210

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?